MCE - Delayed Quote EUR

Biotechnology Assets, S.A. (BST.MC)

Compare
0.3090
+0.0040
+(1.31%)
At close: January 10 at 5:35:17 PM GMT+1
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
3,601.4400
3,601.4400
2,613.7550
3,085.3137
2,524.5899
Cost of Revenue
106.9605
106.9605
-20.8592
49.7860
-196.7558
Gross Profit
3,494.4794
3,494.4794
2,634.6142
3,035.5277
2,721.3457
Operating Expense
516.0960
516.0960
4,340.3551
4,572.2852
3,898.5174
Operating Income
2,978.3834
2,978.3834
-1,705.7410
-1,536.7575
-1,177.1717
Net Non Operating Interest Income Expense
-578.9407
-578.9407
-368.4487
-1,340.1614
-364.7012
Pretax Income
2,322.3665
2,322.3665
-2,042.7529
-2,910.1790
-1,554.6475
Tax Provision
748.5823
748.5823
-98.9922
103.4692
150.3388
Net Income Common Stockholders
1,573.7716
1,573.7716
-1,943.3623
-3,012.8976
-8,606.6083
Diluted NI Available to Com Stockholders
1,573.7716
1,573.7716
-1,943.3623
-3,012.8976
-8,606.6083
Basic EPS
0.03
0.03
-0.04
-0.07
-0.22
Diluted EPS
0.03
0.03
-0.04
-0.07
-0.22
Basic Average Shares
57,725.6030
57,725.6030
54,201.1630
45,614.1110
39,191.2150
Diluted Average Shares
57,725.6030
57,725.6030
54,201.1630
45,614.1110
39,191.2150
Total Operating Income as Reported
2,654.0293
2,654.0293
-1,728.8984
2,073.5068
-1,208.5933
Rent Expense Supplemental
132.8760
132.8760
160.5050
132.6673
90.7946
Total Expenses
623.0565
623.0565
4,319.4960
4,622.0712
3,701.7616
Net Income from Continuing & Discontinued Operation
1,573.7716
1,573.7716
-1,943.3623
-3,012.8976
-8,606.6083
Normalized Income
1,610.4440
1,610.4440
-1,943.3623
-2,977.7280
-1,704.5025
Interest Income
2.2649
2.2649
0.1611
4.2265
0.0854
Interest Expense
310.9676
310.9676
345.4525
854.6725
333.3650
Net Interest Income
-578.9407
-578.9407
-368.4487
-1,340.1614
-364.7012
EBIT
2,633.3341
2,633.3341
-1,697.3004
-2,055.5065
-1,221.2826
EBITDA
5,098.9480
5,098.9480
450.3997
-25.0301
993.1123
Reconciled Cost of Revenue
106.9605
106.9605
-20.8592
49.7860
-196.7558
Reconciled Depreciation
2,465.6140
2,465.6140
2,147.7000
2,030.4764
2,214.3949
Net Income from Continuing Operation Net Minority Interest
1,573.7716
1,573.7716
-1,943.3623
-3,012.8976
-1,704.5025
Total Unusual Items Excluding Goodwill
-54.1160
-54.1160
--
-46.8929
--
Total Unusual Items
-54.1160
-54.1160
--
-46.8929
--
Normalized EBITDA
5,153.0640
5,153.0640
450.3997
21.8628
993.1123
Tax Rate for Calcs
0.0003
0.0003
0.0000
0.0003
0.0003
Tax Effect of Unusual Items
-17.4435
-17.4435
--
-11.7232
--
12/31/2020 - 1/26/2012

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ANW.F Immuron Limited
0.0400
+2.56%
 
ORYZF Oryzon Genomics S.A.
1.6200
0.00%
 
DRTSW Alpha Tau Medical Ltd.
0.2510
+19.52%
 
CYTOF Altamira Therapeutics Ltd.
0.1690
+20.71%
 
ORY.MC Oryzon Genomics S.A.
1.5200
-0.26%
 
IMRN Immuron Limited
1.9500
-3.94%
 
PHM.MC Pharma Mar, S.A.
77.20
-1.72%
 
ROVI.MC Laboratorios Farmaceuticos Rovi, S.A.
63.50
+1.44%
 
DRTS Alpha Tau Medical Ltd.
3.2300
-9.01%
 
ONVO Organovo Holdings, Inc.
0.4001
-7.92%